JOHN MARAGANORE - 10 Dec 2021 Form 4 Insider Report for ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Role: Chief Executive Officer, Director
Signature: By: /s/ Mary Beth DeLena, Attorney-in-Fact For: John M. Maraganore
Issuer symbol: ALNY
Transactions as of: 10 Dec 2021
Transactions value $: $399,829
Form type: 4
Filing time: 14 Dec 2021, 15:05:49 UTC
Previous filing: 12 Nov 2021
Next filing: 23 Dec 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ALNY	Common Stock	Options Exercise	$99,922	+1,036	+0.48%	$96.45	215,801	10 Dec 2021	Direct
transaction	ALNY	Common Stock	Options Exercise	$99,979	+1,124	+0.52%	$88.95	216,925	10 Dec 2021	Direct
transaction	ALNY	Common Stock	Options Exercise	$99,950	+839	+0.39%	$119.13	217,764	10 Dec 2021	Direct
transaction	ALNY	Common Stock	Options Exercise	$99,976	+2,368	+1.09%	$42.22^*	220,132	10 Dec 2021	Direct
holding	ALNY	Common Stock						3,133	10 Dec 2021	by Managed Account	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ALNY	Stock Option (right to buy)	Options Exercise	$0	-2,368	-9.47%	$0	22,632	10 Dec 2021	Common Stock	2,368	$42.22	Direct	F2
transaction	ALNY	Stock Option (right to buy)	Options Exercise	$0	-1,124	-1.73%	$0	63,876	10 Dec 2021	Common Stock	1,124	$88.95	Direct	F2
transaction	ALNY	Stock Option (right to buy)	Options Exercise	$0	-1,036	-1.38%	$0	73,964	10 Dec 2021	Common Stock	1,036	$96.45	Direct	F2
transaction	ALNY	Stock Option (right to buy)	Options Exercise	$0	-839	-1.6%	$0	51,661	10 Dec 2021	Common Stock	839	$119.13	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
F2	The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.
F3	The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to the remaining shares ratably at the end of each three-month period thereafter over the following thirty-three (33) months.